Nisa Investment Advisors LLC Has $777,000 Holdings in Sarepta Therapeutics, Inc. $SRPT

Nisa Investment Advisors LLC increased its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 41,888.5% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 40,309 shares of the biotechnology company’s stock after purchasing an additional 40,213 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Sarepta Therapeutics were worth $777,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Public Employees Retirement System of Ohio lifted its position in Sarepta Therapeutics by 2.2% during the 2nd quarter. Public Employees Retirement System of Ohio now owns 28,792 shares of the biotechnology company’s stock worth $492,000 after buying an additional 607 shares in the last quarter. State of Michigan Retirement System increased its position in shares of Sarepta Therapeutics by 3.1% in the second quarter. State of Michigan Retirement System now owns 23,600 shares of the biotechnology company’s stock valued at $404,000 after acquiring an additional 700 shares during the last quarter. Thrivent Financial for Lutherans raised its holdings in Sarepta Therapeutics by 3.3% during the second quarter. Thrivent Financial for Lutherans now owns 23,140 shares of the biotechnology company’s stock worth $396,000 after acquiring an additional 744 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in Sarepta Therapeutics by 25.4% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,042 shares of the biotechnology company’s stock worth $69,000 after acquiring an additional 819 shares in the last quarter. Finally, New York Life Investment Management LLC boosted its position in Sarepta Therapeutics by 10.0% during the second quarter. New York Life Investment Management LLC now owns 10,623 shares of the biotechnology company’s stock valued at $182,000 after purchasing an additional 966 shares during the last quarter. Institutional investors own 86.68% of the company’s stock.

Analyst Ratings Changes

Several research analysts have weighed in on SRPT shares. HC Wainwright reaffirmed a “sell” rating on shares of Sarepta Therapeutics in a research report on Wednesday. Mizuho raised shares of Sarepta Therapeutics from a “neutral” rating to an “outperform” rating and raised their target price for the company from $19.00 to $26.00 in a research note on Wednesday, November 5th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Sarepta Therapeutics in a research report on Monday, December 29th. Barclays cut their price target on shares of Sarepta Therapeutics from $22.00 to $20.00 and set an “equal weight” rating for the company in a research note on Wednesday, November 5th. Finally, Wells Fargo & Company lowered their price objective on shares of Sarepta Therapeutics from $50.00 to $45.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 5th. Nine analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and six have given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $33.76.

Insider Transactions at Sarepta Therapeutics

In other news, COO Ian Michael Estepan sold 13,187 shares of the business’s stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average price of $22.31, for a total transaction of $294,201.97. Following the completion of the sale, the chief operating officer owned 193,300 shares in the company, valued at $4,312,523. The trade was a 6.39% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 7.60% of the stock is owned by company insiders.

Sarepta Therapeutics Trading Down 6.5%

SRPT stock opened at $21.31 on Friday. Sarepta Therapeutics, Inc. has a one year low of $10.41 and a one year high of $120.05. The stock has a market cap of $2.23 billion, a price-to-earnings ratio of -7.08, a price-to-earnings-growth ratio of 0.50 and a beta of 0.48. The company has a fifty day moving average price of $20.71 and a two-hundred day moving average price of $19.65. The company has a debt-to-equity ratio of 0.78, a current ratio of 2.95 and a quick ratio of 1.79.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its earnings results on Monday, November 3rd. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.15). The company had revenue of $399.36 million for the quarter, compared to analyst estimates of $331.51 million. Sarepta Therapeutics had a negative return on equity of 4.85% and a negative net margin of 11.25%.The business’s quarterly revenue was down 14.5% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.62 EPS. Equities analysts anticipate that Sarepta Therapeutics, Inc. will post 2.67 EPS for the current year.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.